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Abstract 
 Metabolic syndrome is a cluster of five factors (elevated systolic blood pressure, 
elevated blood glucose, elevated triglycerides, large waist circumference, and decreased 
HDL) that are related to a greater chance of heart disease, stroke, and diabetes. There is 
evidence that metabolic syndrome is correlated with depression, but the directionality and 
mechanism is unclear. There is also dispute in the literature as to whether there is a 
correlation with anxiety and metabolic syndrome. In this study, levels of depression and 
anxiety determined from questionnaires and interviews (Adult Self Report, Child 
Behavior Checklist, Kiddie Schedule for Affective Disorders and Schizophrenia-Present 
and Lifetime, and the Composite International Diagnostic Interview) were compared with 
the five factors of metabolic syndrome in 100 three-person families. In children and 
adolescents, elevated triglycerides were predictive of elevated depressive behavior above 
the age of 12.68 (p <.05), with the significance increasing with age. In adults, anxious 
behavior was predictive of overall metabolic risk, HDL, and waist circumference when 
controlling for age, sex, and SES (p <.01, p <.05, and p < .05 respectively). Additionally, 
a lower SES, older age, greater anxious behavior, and being male were all predictive of 
greater overall metabolic risk. Results implicate an age-moderated difference in how 
metabolic factors affect depression in children, possibly having a mechanism coinciding 
or affected by puberty. In adults, the directionality seems to reverse, with the anxious 
behavior having an effect on the metabolic syndrome factor, possibly related to stress and 
inflammation. Further research is needed to study these mechanisms and elucidate the 
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 Metabolic syndrome is one of the most formidable challenges in contemporary 
public health (Kaur, 2014). The disease, defined as a group of risk factors, including 
visceral obesity, unhealthy blood fat content, high blood pressure, and high blood sugar, 
is associated with three of the six leading causes of death worldwide: cardiovascular 
disease, stroke, and diabetes (WHO World Health Report, 2017). Individuals with 
metabolic syndrome are five times more likely to develop type 2 diabetes, two times 
more likely to develop cardiovascular disease within 5 to 10 years of being diagnosed 
with metabolic syndrome, and 2 to 4 times more likely to suffer a stroke (Alberti et al., 
2009; Alberti, Zimmet, Shaw, & Group, 2005). In the United States, between 2003 to 
2012, the overall prevalence of the syndrome was 33%, with significantly higher rates 
among females (35.6%) than males (30.3%; (Aguilar, Bhuket, Torres, Liu, & Wong, 
2015). Additionally, age is a risk factor for metabolic syndrome, with a prevalence of 
50% in adults over the age of 60 (Aguilar et al., 2015). 
 More specifically, the National Institutes of Health National Heart, Lung, and 
Blood Institute (2016) defines metabolic syndrome as the presence of a cluster of at least 
three of the following factors in an adult over age 21:  
1.) Large waist circumference (>40 inches for men; >35 inches for women) 
2.) High triglycerides (>150 mg/dL) 
3.) Low high-density lipoprotein (HDL), commonly referred to as “good 
cholesterol” (<40 mg/dL for men; <50 mg/dL for women) 
4.) High fasting glucose (>100 mg/dL) 
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5.)  Elevated blood pressure (>130/85 mm HG) 
A BMI classified as “obese” (i.e. over 30 kg/m2), though not an explicit component of the 
NIH’s definition of metabolic syndrome, is also considered a risk factor for metabolic 
problems (Kaur, 2014). Each of these factors is related to metabolic risk, for related, but 
slightly different, reasons. 
 Larger waist circumference is indicative of increased stores of adipose tissue in 
the abdomen, often resulting from low physical activity and the consumption of calorie-
dense foods (Kaur, 2014). Adipose tissue stores triglycerides, and contains a variety of 
cell types, such as adipocytes and immune cells (Halberg, Wernstedt-Asterholm, & 
Scherer, 2008; Schmidt et al., 2015). An adipocyte is an endocrine cell, known to secrete 
substances including cortisol, a stress hormone, and pro-inflammatory factors, such as 
cytokines (Lau, Dhillon, Yan, Szmitko, & Verma, 2005). When these substances are 
secreted, they can cause an adverse metabolic effect, as the adipose tissue’s local 
inflammation proliferates into systemic chronic low-grade inflammation (Trayhurn & 
Wood, 2004). Inflammation often precedes the development of diabetes, and is predictive 
of future weight gain (Engstrom et al., 2003; Rodriguez-Hernandez, Simental-Mendia, 
Rodriguez-Ramirez, & Reyes-Romero, 2013; Thorand et al., 2003). 
HDL (“good cholesterol”) functions by carrying low-density lipoproteins (“bad 
cholesterol”) to the liver, which then removes them. High levels of low-density 
lipoproteins are related to artery hardening, which results in impeded blood flow. 
Therefore, low levels of low-density lipoprotein have negative metabolic effects, whereas 
high levels HDL promote good metabolic health (Mayo Clinic, 2015; American Heart 
Association, 2017).  
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Triglycerides are a measure of the amount of lipids in the blood. They store 
unused calories and provide the body with energy when there is low blood glucose 
between meals. High levels of triglycerides contribute to artery wall thickening and 
hardening, known as atherosclerosis, and are linked to the increased risks of stroke and 
cardiovascular disease (American Heart Association, 2017; Mayo Clinic, 2015). 
Fasting glucose levels are a measure of the amount of glucose in the blood after 
fasting for at least eight hours. Glucose, a simple sugar, is derived from food and is used 
to generate energy for the body’s cells. After eating, glucose enters the bloodstream via 
the intestines, and results in a blood sugar “spike”. After fasting, if levels are high it 
indicates that the body is not utilizing insulin properly for transporting glucose into cells. 
This suggests the presence of diabetes or a prediabetic state, and over time can also lead 
to problems such as heart attacks and strokes (American Diabetes Association, 2017; 
Joslin Diabetes Center, 2017). 
Systolic blood pressure refers to the pressure in the arteries during cardiac muscle 
contraction (ventricular systole). A high systolic blood pressure may be caused by an 
unhealthy lifestyle, medications, and stress-induced vasoconstriction (artery narrowing) 
among other reasons. High systolic blood pressure is a known risk factor of 
cardiovascular disease and stroke (Reece, Wasserman, Campbell, & Yunagisawa, 2011).  
Finally, a high BMI is indicative of large quantities of visceral body fat, and can 
be regarded as a predictor of metabolic syndrome independent of waist circumference. In 
clinical practice and research, BMI can serve as a simple indicator of body fat and 
metabolic risk (Janssen, Heymsfield, Allison, Kotler, & Ross, 2002).   
 
METSYN, ANXIETY, & DEPRESSION 7 
 
Psychological Connections 
 In addition to negative physiological outcomes, several studies have indicated a 
link between metabolic syndrome and psychiatric disorders. In particular, these 
associations have been well studied in relation to schizophrenia and bipolar disorder. 
Metabolic syndrome has a comorbidity rate as high as 60% among individuals with 
schizophrenia (Meyer, Koro, & L'Italien, 2005). The literature suggests many possible 
reasons, including side effects of medication usage, lifestyle, and a common pathogenic 
pathway involving sphingolipids. Amongst their other functions sphingolipids are 
involved in inflammation. Inflammation as a result of obesity can lead to glucose 
intolerance. It can also reduce white matter and myelination in the brain, leading to 
abnormal brain circuitry and psychotic symptoms resulting in schizophrenia (Castillo et 
al., 2016).   
 Bipolar disorder is also associated with a higher risk of metabolic syndrome than 
in the general population (McIntyre et al., 2010). Even when controlling for medication 
and health habits, individuals with bipolar disorder have been shown to be at greater 
cardiovascular risk. This has lead researchers to believe that dysregulated inflammatory 
pathways may underlie these disorders (Leboyer et al., 2012) This pathway is possibly 
mediated by cytokines, which are part of the immune system’s inflammatory response, 
and are elevated during episodes of mania and depression (Leboyer et al., 2012). In a 
study examining metabolic syndrome, schizophrenia, and bipolar disorder, metabolic 
syndrome was more likely to occur in individuals with schizophrenia and bipolar disorder 
than controls, even when controlling for exercise, diet, and smoking (Bly et al., 2014). 
These findings support the multi-systemic nature of bipolar disorder, as it is indicates that 
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its effects are related to more than one body system. In response to this research on 
bipolar disorder and schizophrenia and multi-systemic theories, increased emphasis has 
been placed on conceptualizing and studying psychiatric disorders as disorders of not 
only the mind, but also the body (Leboyer et al, 2012). However, to date, the evidence 
supporting this theory in relation to other psychiatric disorders, namely anxiety and 
depression, remains mixed.  
With regard to anxiety disorders, several studies have identified metabolic 
associations. For example, a study looking at Vietnam war veterans found that a 
diagnosis of generalized anxiety disorder was positively associated with metabolic 
syndrome, whereas depression was not (Carroll et al., 2009). Similarly, another study by 
Luppino and colleagues (2011) found a strong association between most metabolic 
syndrome components and anxiety-specific affects, but not depression-specific affects. 
 By contrast, however, other recent studies have found that the prevalence of 
metabolic syndrome was greater only in individuals with depression, but not anxiety 
(Butnoriene, Bunevicius, Norkus, & Bunevicius, 2014). Another study found that as 
levels of depression increased, the number of components of metabolic syndrome 
exhibited also increased, even when controlling for obesity, smoking status, 
socioeconomic status, age, lifestyle, and comorbidity with anxiety.  This relationship was 
not observed with anxiety symptoms (Skilton, Moulin, Terra, & Bonnet, 2007).  
 Other studies have found no association between depression or anxiety and 
metabolic problems. For example, a study in Finland found that after sex, alcohol 
consumption, smoking, marital status, education level, and physical activity were 
controlled for, metabolic syndrome was not associated with anxiety or depression in 
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young adults (Herva et al., 2006). Affirming these findings, a large longitudinal study 
conducted in Norway found no association between anxiety and depression and future 
metabolic syndrome (Hildrum, Mykletun, Midthjell, Ismail, & Dahl, 2009).  
In summary, the literature on the relations between anxiety, depression and 
metabolic problems remains unclear. To date, the majority of the research has focused on 
depressive disorders and additional research is needed to understand the metabolic effects 
of both anxiety alone and comorbid with depression.  
 
Significance 
More research is needed to investigate the interactions between metabolic 
syndrome, anxiety disorders, and depressive disorders in order to address the 
inconsistencies in the literature and determine if a common mechanism may connect 
these disorders. This is particularly important to understand, as anxiety and depressive 
disorders are very common. In the United States, there is an 18.1% prevalence rate of 
past year anxiety disorders in adults (Kessler, Berglund, et al., 2005; Kessler, Chiu, 
Demler, Merikangas, & Walters, 2005) and a 6.7%, prevalence rate of past year major 
depressive episodes (National Survey on Drug Use and Health, 2016). Given this high 
prevalence, it is important to research to have scientific consensus regarding whether 
these disorders may be a risk factor for metabolic syndrome, or its components. This will 
enable further research into specific mechanisms and associations, which can help   
improve treatments, diagnoses, and screening. As stated by Chapman and colleagues, 
“Research examining the association between depressive disorders and chronic disease 
suggests that timely diagnosis and treatment of psychiatric disorders could greatly affect 
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the impact of chronic disease. The presence of mental illness may be an important 
contributor to the etiology of chronic disease. Thus, the promotion of mental health 
would likely result in reducing a considerable proportion of the burden of chronic 
disease.” (Chapman, Perry, & Strine, 2005). There is sufficient evidence to believe that 
this rationale could be extended to anxiety and depressive disorders.  
Furthermore, understanding the relations between these disorders may also help 
control the cost of healthcare. In the United States, 75% of healthcare finances are spent 
on chronic diseases. The Centers for Disease Control and Prevention (CDC), reported 
that $313.8 billion dollars were spent on cardiovascular disease and stroke in 2009, as 
well as $116 billion spent on diabetes in 2007 (2009). In contrast with the costs of 
depression and anxiety, which average $210.5 billion and $42 billion per year, 
respectively. Therefore, if a connection between anxiety and depression can be 
empirically established, it is possible that early identification and treatment of depression 
and anxiety could prevent the development of more costly and chronic metabolic 
conditions. This has the potential to reduce healthcare cost by billions of dollars 
(Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015; Greenberg et al., 1999).                                                                                                                                                          
Finally, a novel element of the current study is that it examines metabolic 
symptoms in relation to anxiety and depression in both adults and children. While 
previous studies have looked at obesity and anxiety and depression in children, to our 
knowledge, the specific associations between elevated metabolic syndrome components 
and anxiety and depression symptoms have not been examined (Anderson, Cohen, 
Naumova, Jacques, & Must, 2007; Weiss et al., 2004). It is important to understand the 
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development of disorders from an early age, as it can lead to earlier screening, 
identification and intervention. 
 
Hypotheses 
Based on the existing literature, it was hypothesized that all of the individual 
components of metabolic syndrome would be positively correlated with the presence of 
depressive symptoms. As the literature indicates that depression is correlated with 
metabolic syndrome more often than anxiety, it was also hypothesized that the presence 
of anxiety symptoms would not be significantly correlated with metabolic syndrome 
components. Finally, it was hypothesized that the relations between anxiety, depression, 
and metabolic syndrome components would be consistent for adults and children. As 
there is a lack of literature looking at children, adults, and metabolic syndrome, there was 




 This study constitutes a secondary analysis of data obtained from a family study 
on emotion regulation conducted in the University of Vermont Child Emotion Regulation 
Laboratory under the direction of Dr. Robert Althoff (Committee on Human Research in 
Medical Sciences #13-275). Eighty-three family units, each consisting of one proband 
accompanied by either two biological parents, or one biological parent and one full 
biological sibling, were recruited from both a pediatric psychiatry clinic and the 
community. In addition to the presence of biological family members, recruitment criteria 
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for the proband included either the presence of emotion dysregulation problems, or the 
ability to be a clean control or psychiatric control. Subjects were chosen for this 
secondary analysis based on the availability of questionnaire, blood draw, and 
morphometric data. 
As seen in Table 1, the mean socioeconomic status of families in this sample was 
65.43 on the Hollingshead scale, which corresponds to middle class status. There were 
140 total children, of which 65.7% of the children in the sample were male (0=female, 
1=male) and the mean age was 11.36 years. All children were between the ages of 7 to 
17. Among the children there were 56 sibling pairs in the sample. There were 117 adults, 
with 30.8% of the sample being male (0=female, 1=male), and a mean age of 43.51 
years. 
The original purpose of this study was to examine the relations between emotion 
dysregulation and metabolic problems. Therefore, the mean level of emotional-behavioral 
problems was higher in the children than in the general population. Based on the Child 
Behavior Checklist, the average score for total emotional-behavioral problems was at the 
69th percentile. More specifically, the mean level of withdrawn and anxious symptoms 
were at the 71st and 69th percentile, respectively, for children in this sample. Adults had a 
slightly above average total problems score in the 54th percentile. They had an average 
withdrawn score in the 63rd percentile and an average anxious-depressed score in the 67th 
percentile. Written informed consent and assent was obtained from all subjects prior to 
participation in the study. No exclusions were made based on sex, race, or ethnic 
background. 
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Measures  
Child Behavior Checklist 
The Child Behavior Checklist (CBCL) is a parent-report questionnaire that 
assesses children’s emotional, behavioral and social problems during the past 6 months.  
The questionnaire consists of 113 problem items that are rated on a 3-point scale of 0 
(“Not true”), 1 (“Somewhat or Sometimes True”), or 2 (“Very True or Often True”), 
which have been factor-analytically reduced to 8 syndrome scales that are consistent 
across age, informant, and culture (Achenbach & Rescorla, 2001). The psychometrics of 
these scales have been well characterized with test-retest reliabilities ranging from 0.74 to 
0.95 and Cronbach alphas ranging from 0.79 to 0.97. For the purposes of this study, raw 
scores on the Anxious-Depressed and Withdrawn-Depressed syndrome scales were used. 
Because most parents in the sample were mothers, whenever available, the maternal 
report was used for consistency. 
 
Adult Self Report 
 The Adult Self Report (ASR) is a self-report questionnaire analogous to the 
CBCL, that assesses emotional, behavioral, social, and substance use problems during the 
past 6 months. Similar to the CBCL, adults reported on problem behaviors on a 3-point 
scale for 123 problem items. These items have been factor-analytically reduced to 8 
syndrome scales that are consistent across age, informant, and culture. The psychometrics 
for these scales have been well characterized with rest-retest reliabilities ranging from 
0.87 to 0.91 and Cronbach alphas ranging from 0.83 to 0.88. For this study, raw scores on 
the Anxious-Depressed and Withdrawn-Depressed syndrome scales were used. 
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Blood Draw and Morphometric Data 
 In accordance with the recommendations of the National Cholesterol Education 
Program (NCEP), height, weight, and waist circumference (measured halfway between 
the iliac crest and the lowest rib), blood pressure and resting heart rate data were 
collected from all participants. Body Mass Index (BMI) was calculated from height and 
weight.  
Additionally, a blood sample was taken to obtain plasma glucose, triglycerides, 
HDL, and insulin measurements. Participants were required to fast for at least eight hours 
prior to the blood draw. After the blood draw, participants were given $5.00 vouchers to 
purchase breakfast at the University of Vermont Medical Center Dining Facilities. If 
adults were treated for hypertension, diabetes, or hyperlipidemia, the type and dosage of 
medication was recorded. In order to standardize the scales for each morphometric and 
metabolic factor (waist circumference, systolic blood pressure, fasting glucose, high-
density lipoproteins, and triglycerides), the factors were first z-transformed. High-density 
lipoprotein scores were transformed so that higher scores would reflect lower levels, and 
therefore, a greater metabolic risk. Then, the factors that comprise metabolic syndrome 
were averaged to compute overall metabolic risk. Due to a smaller sample size for data 
from the blood draw (ntotal = 178, nkids = 89, nadults = 89) the Z scores were not summed in 
order to avoid underestimating metabolic risk for people with missing data. The 
metabolic risk score was calculated separately for the full sample, for adults only, and for 
children only.  
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Statistics 
 Pearson’s correlation and multiple hierarchical regression analyses were 
conducted using IBM SPSS Statistics version 24. Then, the PROCESS macro 2.16 was 
used to conduct follow-up simple slope analyses to examine the nature of interaction 
effects (Hayes, 2016).  
 
Results 
Tables 1 and 2 present the descriptive statistics and Pearson’s correlations 
between all variables of interest. Using the results of the Pearson’s correlations, analyses 
were initially run on the full sample, and then broken down into adults and children. 
 
Full Sample 
A hierarchical multiple regression analysis was conducted predicting the overall 
metabolic risk for the full sample. At step one, SES, sex, and age were entered as 
covariates. At step two, anxious-depressed symptoms were added to the model. The 
overall model was significant and accounted for 35% of the variability in the overall 
metabolic risk score (R2 .35, F [4, 192] = 25.81, p <.001) with the addition of anxious-
depressed symptoms uniquely contributing 1.4% of the variance (ΔR2 = .01, ΔF [1, 192] 
= 4.20, p <.05). More specifically, age (b = .02, t[192] = 8.32, p <.001), and anxious-
depressed symptoms (b = .02, t[192] = 2.05, p < .05) had significant positive effects on 
overall metabolic risk. SES (b = -.01, t[192] = -3.38, p = .001) had a significant negative 
effect on overall metabolic risk, and sex (b = .52, t[192] = 5.61, p <.001) had an effect 
such that males had a higher metabolic risk than females. The same procedure was 
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repeated using withdrawn-depressed symptoms at step two to predict overall metabolic 
risk. The model was significant and predicted 33% of the variance in withdrawn-
depressed symptoms (R2 =.33, F [4, 192] = 25.20, p <.001). However, the addition of 
withdrawn-depressed symptoms at step two was not significant.  
 
Adults 
We repeated the hierarchical multiple regression analysis to investigate anxious-
depressed symptoms on overall metabolic risk in adults only. Sex, age, and SES were 
used in step one of the analysis to predict overall metabolic risk in adults. In step two, 
anxious-depressed symptoms were added. The overall model was significant, accounting 
for 38% of the variability in metabolic risk (R2 = .38, F [4, 92] = 13.92, p <.001). The 
addition of anxious-depressed symptoms uniquely contributed 4.8% of the variance (ΔR2 
=.05, ΔF [1, 92] = 7.07, p <.01). Age (b = .03, t[92] = 2.84, p < .01) and anxious-
depressed symptoms (b = .03, t[92] = 2.66, p < .01) had positive significant effects on 
metabolic risk, whereas SES (b = -.007, t[92] = -2.36, p < .05) had a significant negative 
effect on metabolic risk. Sex (b = .71, t[92] = 5.39, p <.001) also had an effect such that 
adult males had a higher metabolic risk than adult females. 
To further investigate the relations between anxious-depressed symptoms and 
metabolic problems, we conducted hierarchical multiple regressions predicting each of 
the individual metabolic components that were significantly correlated with anxious-
depressed symptoms in Table 2. In the first regression with HDL as the dependent 
variable, age, sex, and SES were entered at step one. In step two, anxious-depressed 
symptoms were added. The overall model was significant, accounting for 21% of the 
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variance in HDL (R2 = .21, F [4, 74] = 4.97, p <.001), with anxious-depressed symptoms 
uniquely accounting for 5.4% of the variance (ΔR2 =.05, ΔF [4, 74] = 5.07, p <.05). 
Anxious-depressed symptoms (b = .04, t[74] = 2.25, p <.05) had a significant positive 
effect on HDL. Sex (b = .82 t[74] = 3.72, p <.001) also had an effect such that being male 
was associated with having lower levels of HDL.  
This model was repeated predicting waist circumference. The overall model was 
significant, predicting 32% of the variance in waist circumference (R2 =.32, F [4, 91] = 
10.79, p <.001) with anxious-depressed symptoms uniquely predicting 4.4% of the 
variance in waist circumference (ΔR2 =.04, ΔF [1, 91] = 5.86, p <.05). SES (b = -.01 
t[91] = -2.90, p < .01) had a significant negative effect, anxious-depressed symptoms (b = 
.03 t[91] = 2.42, p <.05) had a significant positive effect, and sex (b = .75 t[91] = 4.39,    
p <.001) was significant such that to being male was associated with waist circumference. 
Finally, the third iteration of this model predicting BMI was statistically significant, 
predicting 17.2% of the variance (R2 =.17, F [4, 90] = 4.68, p <.01). However, the 
addition of anxious-depressed symptoms did not uniquely contribute to the significance. 
Further analyses examining the possibility of interactions effects of between age, sex, and 
SES with anxious-depressed symptoms on HDL, and waist circumference did not yield 
significant findings.  
Additionally, to investigate the possibility that metabolic problems may predict 
anxious-depressed symptom, additional hierarchical multiple regression analyses were 
conducted with anxious-depressed symptoms as the dependent variable. In step one, age, 
sex, and SES were entered. In step two, HDL was entered. In step three, waist 
circumference was added followed by BMI in step four. No significant effects were 
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found, indicating that, in adults, anxious-depressed symptoms are more predictive of 
metabolic problems than vice versa. The analysis was repeated with withdrawn-depressed 
symptoms as the dependent variable, and there were also no significant findings. 
 
Children  
Sex, age, and socioeconomic status were used in step one of a hierarchical 
multiple regression analysis to predict overall metabolic risk in children and adolescents. 
In step two, anxious-depressed symptoms were added. The overall model was significant, 
and predicted 26.3% of the variability in metabolic risk (R2 = .26, F [4, 95] = 8.46,          
p <.001). However, the addition of anxious-depressed symptoms was not significant.  
Next, we performed additional hierarchical multiple regressions predicting each 
of the metabolic risk factors that were significantly correlated with anxious-depressed 
and withdrawn symptoms. First, using withdrawn symptoms as the dependent variable, 
age, SES, and sex were entered at step one of the regression. At step two, triglycerides 
were added, followed by waist circumference at step three, and BMI at step four. The 
overall model predicted 21% of the variance in withdrawn-depressed symptoms (R2 =.21, 
F [6, 64] = 2.84, p < .05). Though the overall model was significant, none of the 
individual predictors had significant independent effects on withdrawn-depressed 
symptoms, suggesting a possible interaction effect. The analysis was repeated, predicting 
anxious-depressed symptoms, and was not significant. 
To examine possible interactive effects on withdrawn-depressed symptoms, we 
computed cross product terms of “age x triglycerides”, and added it as a fifth step to the 
model. The addition of the interaction term significantly improved the overall model, 
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which now predicted 25% of the variance in withdrawn-depressed symptoms (R2= .25, F 
[7, 63] = 3.05, p <.01). The interaction of age x triglycerides uniquely predicted 4.3% of 
the variance, which was a marginally significant increase (ΔR2 =.04, ΔF [1, 63] = 3.59, p 
= .063). To further explore this interaction, we used PROCESS to conduct follow-up 
simple slope analyses at values of +/-1 standard deviation for age and triglycerides. For 
younger children (-1 standard deviation), there was no significant effect of triglycerides 
on withdrawn-depressed symptoms. However, for older children (+1 standard deviation), 
there was a significant positive effect of triglycerides on withdrawn symptoms (b = .47, 
t[63] = 2.47, p < .05; see Figure 1). Additionally, the Johnson-Neyman technique was 
used to identify regions of significance, indicating a statistically significant effect of 
triglycerides on withdrawn scores for children over the age of 12.68 years.  
There were no significant interactions of between other variables in the model. 
Finally, meeting full criteria for metabolic syndrome did not significantly predict 
anxious-depressed or withdrawn symptoms in children 
 
Discussion 
 The purpose of this study was to evaluate if there was a connection between 
metabolic syndrome and anxiety and depression. The findings of the study partially 
support the hypothesis, as anxiety was related to metabolic syndrome components in 
adults and depression was related to metabolic syndrome components in children. 
Although in the full sample, 1.4% of the overall metabolic risk was uniquely predicted by 
anxious-depressed symptoms, further analyses indicated that the relations of anxious-
depressed symptoms and metabolic risk in adults drove this effect. Anxious-depressed 
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symptoms predicted of 4.8% of the variance in overall metabolic risk in adults, and had 
an effect such that higher levels of anxious-depressed symptoms were associated with 
greater metabolic risk. Additionally, being older, male and of lower SES background 
were risk factors for higher overall metabolic risk, lower levels of good cholesterol and a 
large waist circumference. This finding is consistent with previous research insofar as 
low SES and age have been previously identified as risk factors for metabolic syndrome 
(Hildrum, Mykletun, Hole, Midthjell, & Dahl, 2007; Matthews, Raikkonen, Gallo, & 
Kuller, 2008). However, inconsistent with the literature, most research has found that 
women tend to have a greater risk of metabolic syndrome than men (Beigh & Jain, 2012; 
Tonstad, Sandvik, Larsen, & Thelle, 2007). These inconsistencies may be due to the large 
proportion of female adults in this sample of which may have reduced this studies ability 
to detect effects of anxiety or depression on metabolic risk for males. Additionally, most 
participants in this study resided in Vermont, a state that is healthier than other areas in 
the United States (United Health Foundation America’s Health Rankings, 2016).  
In adults, only anxious-depressed symptoms predicted metabolic problems, 
specifically waist circumference and high-density lipoproteins. This finding is contrary to 
the hypotheses that depression, but not anxiety would be related to all the components of 
metabolic syndrome. This finding provides further evidence that anxiety is related to 
metabolic problems, and supports the assertion that more research should be done 
investigating anxiety and metabolic outcomes.  
 Inferences from the data imply anxiety may have a negative metabolic effect, 
whereas depression may not. This may be explained by the fact that anxiety is a 
psychological reaction to stress, even if the stressor is no longer present (Faravelli & 
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Pallanti, 1989; Finlay-Jones & Brown, 1981; Schneiderman, Ironson, & Siegel, 2005).  
Additionally, people with high levels of stress may have altered eating habits, choosing to 
eat higher-calorie foods and increase overall consumption (Zellner et al., 2006). High 
levels of stress are related to emotional eating, weight gain around the abdomen, and 
increased blood pressure, all factors that contribute directly or indirectly to metabolic 
syndrome (A. Chao et al., 2016). Behavioral changes, such as increased physical activity, 
improved eating habits, and stress reduction techniques, such as meditation or 
mindfulness may serve to both alleviate anxiety and reduce its negative metabolic 
consequence (Daubenmier et al., 2011; Salmon, 2001). 
In particular, large waist circumference and low HDL levels were the metabolic 
risk factors predicted by anxious-depressed symptoms. Increased adipose tissue around 
the abdomen contributes to lower levels of HDL (Nguyen-Duy, Nichaman, Church, Blair, 
& Ross, 2003). Increased visceral adipose tissue has been shown to be a consequence of a 
stress-induced cortisol response (Moyer et al., 1994). Negative metabolic outcomes may 
be caused by an increase in the stress hormone cortisol due to chronic stress in 
individuals with anxiety (A. M. Chao, Jastreboff, White, Grilo, & Sinha, 2017). A 
proposed mechanism is that increased interleukins (cytokines) stimulate the release of 
cortisol (Urwyler, Schuetz, Ebrahimi, Donath, & Christ-Crain, 2017). In a recent study, 
interleukin antagonism in obese participants was found to lead to a decrease in cortisol, 
systolic blood pressure, and heart rate (Urwyler et al., 2017). Anxiety, through stress and 
cortisol release, may be related to negative metabolic outcomes. This relates anxiety to 
metabolic syndrome.  
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Unlike in adults, anxious-depressed symptoms did not predict metabolic outcomes 
in children. However, the interaction between age and triglycerides did have an effect on 
withdrawn-depressed symptoms, such that for children over the age of 12.68 years of age, 
high levels of triglycerides were associated with more severe withdrawn-depressed 
symptoms, whereas for children under the age 12.68, triglycerides had no effect. This is 
in contrast with the hypothesis that the relations between anxiety, depression and 
metabolic problems would be consistent across age. It is possible that triglyceride accrual 
around the age of puberty may increase the risk of depressive symptoms, possibly related 
to self-esteem and body dissatisfaction in adolescents, especially as steady weight gain 
and increased body fat is associated with the onset of puberty (Lehrer, 2015; Ozmen et 
al., 2007). This is further supported by a substantial body of research that has suggests 
that obesity, which is associated with high triglyceride levels, may contribute to the early 
onset of puberty (Ahmed, Ong, & Dunger, 2009). The early onset of puberty is also a risk 
factor for depression (Birmaher et al., 1996; Wang, Lin, Leung, & Schooling, 2016; 
Weissman, Warner, Wickramaratne, Moreau, & Olfson, 1997). It is possible that high 
triglycerides may lead to weight gain, premature puberty, and depressive symptoms 
during adolescence.  
It is noteworthy, that in adults, internalizing psychiatric symptoms (e.g. anxious-
depressed) were found to uniquely contribute to metabolic risk, whereas in children, the 
inverse relationship was observed. That is, in children, metabolic risk (specifically 
triglycerides) uniquely predicted internalizing symptoms (i.e. withdrawn-depressed). This 
may reflect an age-specific effect or separate mechanistic pathways. It is possible that 
similarly to schizophrenia and bipolar disorder, inflammatory processes may underlie 
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both the psychiatric and physiological symptoms in some individuals with anxiety and 
depression. However, isolating those mechanisms was beyond the scope of the present 
study. This study demonstrated a connection between symptoms of anxiety and 
depression and metabolic problems, supporting the necessity for further research into the 
cellular mechanisms of the disorders.  
 
Limitations & Future Directions 
 This study had several limitations. First, because the design of the study was 
cross-sectional, we could not make temporal inferences regarding the directionality of the 
relations between anxiety and depression symptoms and metabolic problems. 
Additionally, lifestyle (e.g. exercise, diet), medication usage, and comorbidity were not 
controlled for in this study. Because these factors may have been related to both 
psychiatric and metabolic symptoms, it will be important to examine these effects in 
future research. 
 A larger sample size and more even ratios of females to males would also make 
the study more generalizable. Additionally, as the participants were part of a family 
study, and thus shared genetics and environment, there may have been an inflated 
likelihood of significant findings.  
Future directions include adding diet, exercise, biological relatedness, and 
medication use to the hierarchical regression model. This can help to elucidate the impact 
each of these factors has on psychological wellbeing and metabolic syndrome 
components. Future studies should investigate participants longitudinally, as this can help 
to determine directionality. Lastly, it would be interesting to look at this data set in 
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relation to emotional eating and the HPA (hypothalamic-pituitary-adrenal) axis. This is 
the idea that stress causes an increased desire for calorie-dense food. When comfort food 
is eaten, it may alter signals in the brain, lowering the response to stress (Yau & Potenza, 
2013). The HPA axis could be examined in part by adding blood cortisol levels, delay 
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   Children 
N=140 
  Adults 
N=117 
  
 Sex SES Age Sex SES Age Sex SES Age 
Mean .50 65.98 26.00 .66 65.43 11.36 .31 66.65 43.51 
Standard 
Deviation 
.50 22.97 16.76 .48 23.99 2.81 .46 21.73 6.51 
Minimum 0  0 7 0 0 7 0 0 28 
Maximum 1  90 60 1 90 17 1 90 60 
N 257 251 257 140 139 140 117 112 117 
Missing (N) 0 6 0 0 1 0 0 5 0 
% Male 50.2 - - 65.7 - - 30.8 - - 
% Female 49.8 - - 34.3 - - 69.2 - - 
 



























































**p<.01, *p <.05 (2-tailed) 


























All Subjects Average Z Score .235** .119 
Adults Average Z Score .245* .108 
Children Average Z Score .132 .263** 
Children & Adults Average Z 
Score 
.169* .191* 
BMI .296** .140* 
BMI Children Average Z Score .195 .358** 
BMI Adults Average Z Score .228* .134 
Waist Circumference All 
Subjects Average Z Score 
.286** .146* 
Waist Circumference Adults 
Average Z Score 
.257* .150 
Waist Circumference Children 
Average Z Score 
.132 .292** 
HDL Adult Average Z Score .215 .043 
Triglycerides Children Average 
Z Score 
.198 .286* 
Metabolic syndrome Diagnosis .077 .039 
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Triglycerides Z Score 
Younger Children
Older Children
